Phase I Dose-Escalation Study of CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma
Summary
The purpose of this phase I study is to evaluate the safety and tolerability of CPI-613 in combination with gemcitabine and radiation therapy (Gem-RT) in patients with pancreatic adenocarcinoma.
General Information
NCT#: NCT05325281
Study ID: PRO00043904
Trial Phase: Phase I
Trial Sponsor: Cornerstone Pharmaceuticals, Medical College of Wisconsin
Therapies Used in This Trial: Gemcitabine, Radiation Therapy, CPI-613